Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 7 | 2022 | 398 | 2.000 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2022 | 34 | 1.410 |
Why?
|
| Catheter Ablation | 2 | 2021 | 220 | 1.160 |
Why?
|
| Hemorrhage | 2 | 2020 | 260 | 1.160 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2021 | 365 | 1.100 |
Why?
|
| Coronary Artery Disease | 3 | 2020 | 216 | 0.850 |
Why?
|
| Cannabinoids | 1 | 2022 | 8 | 0.780 |
Why?
|
| Coronary Thrombosis | 1 | 2022 | 36 | 0.770 |
Why?
|
| Cardiomyopathies | 2 | 2018 | 33 | 0.710 |
Why?
|
| Secondary Prevention | 1 | 2020 | 44 | 0.690 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 53 | 0.650 |
Why?
|
| Aspirin | 1 | 2020 | 122 | 0.650 |
Why?
|
| Cardiac Tamponade | 1 | 2019 | 8 | 0.630 |
Why?
|
| Pericardial Effusion | 1 | 2019 | 12 | 0.630 |
Why?
|
| Pyridones | 1 | 2019 | 33 | 0.620 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2019 | 117 | 0.620 |
Why?
|
| Pyrazoles | 1 | 2019 | 62 | 0.610 |
Why?
|
| Competency-Based Education | 1 | 2018 | 16 | 0.610 |
Why?
|
| Internal Medicine | 1 | 2018 | 28 | 0.600 |
Why?
|
| Peripartum Period | 1 | 2018 | 4 | 0.600 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 38 | 0.600 |
Why?
|
| Cardiology | 1 | 2018 | 47 | 0.600 |
Why?
|
| Puerperal Disorders | 1 | 2018 | 14 | 0.590 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 15 | 0.590 |
Why?
|
| Treatment Outcome | 9 | 2022 | 2286 | 0.540 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2020 | 287 | 0.510 |
Why?
|
| Risk Factors | 6 | 2021 | 2038 | 0.480 |
Why?
|
| Humans | 21 | 2022 | 27169 | 0.460 |
Why?
|
| Heart Failure | 3 | 2022 | 234 | 0.450 |
Why?
|
| Atrial Appendage | 2 | 2022 | 31 | 0.390 |
Why?
|
| Obesity | 1 | 2018 | 655 | 0.390 |
Why?
|
| Observational Studies as Topic | 3 | 2021 | 53 | 0.390 |
Why?
|
| Ventricular Function, Left | 3 | 2022 | 101 | 0.340 |
Why?
|
| Female | 11 | 2022 | 14662 | 0.300 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 190 | 0.300 |
Why?
|
| Adult | 4 | 2022 | 7506 | 0.280 |
Why?
|
| Stroke Volume | 4 | 2022 | 111 | 0.270 |
Why?
|
| Middle Aged | 9 | 2022 | 6913 | 0.270 |
Why?
|
| Male | 10 | 2022 | 13040 | 0.270 |
Why?
|
| Aged | 8 | 2022 | 5234 | 0.230 |
Why?
|
| Time Factors | 5 | 2021 | 1571 | 0.230 |
Why?
|
| Risk Assessment | 4 | 2020 | 598 | 0.220 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 205 | 0.200 |
Why?
|
| Coronary Angiography | 1 | 2022 | 150 | 0.190 |
Why?
|
| Women | 1 | 2021 | 12 | 0.180 |
Why?
|
| Recovery of Function | 2 | 2018 | 112 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2022 | 397 | 0.180 |
Why?
|
| Administration, Oral | 1 | 2021 | 166 | 0.180 |
Why?
|
| Young Adult | 2 | 2018 | 2633 | 0.180 |
Why?
|
| Rivaroxaban | 1 | 2020 | 28 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 1944 | 0.170 |
Why?
|
| Incidence | 2 | 2021 | 553 | 0.170 |
Why?
|
| Publishing | 1 | 2020 | 30 | 0.170 |
Why?
|
| Risk | 1 | 2020 | 133 | 0.170 |
Why?
|
| Mass Screening | 1 | 2021 | 149 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 26 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2020 | 97 | 0.160 |
Why?
|
| Pancreatitis | 1 | 2019 | 36 | 0.160 |
Why?
|
| Primary Health Care | 1 | 2021 | 152 | 0.160 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 39 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 28 | 0.160 |
Why?
|
| Pericardiocentesis | 1 | 2019 | 4 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 206 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2020 | 93 | 0.160 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 26 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2021 | 293 | 0.150 |
Why?
|
| Stroke | 1 | 2022 | 241 | 0.150 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Blindness | 1 | 2018 | 34 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 45 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 64 | 0.150 |
Why?
|
| Heart Ventricles | 1 | 2018 | 133 | 0.150 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2018 | 65 | 0.150 |
Why?
|
| Quality of Life | 1 | 2022 | 468 | 0.150 |
Why?
|
| Echocardiography | 1 | 2018 | 108 | 0.140 |
Why?
|
| Autonomic Nervous System | 1 | 2018 | 112 | 0.140 |
Why?
|
| Electric Countershock | 1 | 2017 | 29 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 28 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2017 | 25 | 0.140 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 45 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 123 | 0.130 |
Why?
|
| Sex Factors | 1 | 2018 | 452 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2018 | 387 | 0.130 |
Why?
|
| Heart Rate | 1 | 2018 | 375 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 357 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 163 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2018 | 228 | 0.120 |
Why?
|
| Pregnancy | 1 | 2018 | 1154 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 516 | 0.110 |
Why?
|
| United States | 1 | 2018 | 2070 | 0.100 |
Why?
|
| Hospitals | 2 | 2022 | 72 | 0.100 |
Why?
|
| Inpatients | 2 | 2022 | 56 | 0.100 |
Why?
|
| Prevalence | 2 | 2021 | 478 | 0.080 |
Why?
|
| Age Factors | 2 | 2021 | 725 | 0.070 |
Why?
|
| Oklahoma | 2 | 2021 | 979 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2021 | 1221 | 0.070 |
Why?
|
| Off-Label Use | 1 | 2020 | 6 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 243 | 0.040 |
Why?
|
| Journal Impact Factor | 1 | 2020 | 8 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 763 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2019 | 7 | 0.040 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 14 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2019 | 34 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 50 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 391 | 0.040 |
Why?
|
| Pancreas | 1 | 2019 | 59 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 202 | 0.040 |
Why?
|
| Diastole | 1 | 2018 | 22 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 98 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 317 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 132 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 989 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 162 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 405 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 608 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 367 | 0.030 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2017 | 18 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 85 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 144 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 466 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 230 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 931 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 143 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 375 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 811 | 0.030 |
Why?
|